Vicapsys Acquires NitroMist and Establishes Federal Supply Channels
What happened
Vicapsys Life Sciences, Inc. completed a reverse merger with Stateline Distributors of Puerto Rico, Inc. on September 3, 2026, and acquired the FDA-approved NitroMist® (nitroglycerin) lingual aerosol product via a definitive asset purchase agreement. The combined company now operates as a pharmaceutical distributor and has established access to federal contracting channels, including Indian Health Service pharmaceutical supply.
From pr-inside.com
Why it matters
The acquisition and establishment of federal supply channels allow the combined company to participate in government healthcare procurement. This access is significant for the distribution and sales of the specialized pharmaceutical product.
From pr-inside.com
Who's involved
- FDAThe regulatory body whose approval is required for the product.
- Indian Health ServiceA federal supply channel the combined company can access for pharmaceutical distribution.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Indian Health ServiceSpeculative
The Indian Health Service might see changes in pharmaceutical supply contracts due to the combined company's new access.
Keep exploring
The entities involved
- FDA
-
Puerto Rico
unincorporated territory of the United States of America
Related events
- FDA approval supports NDA submission in Aurora.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- NIH is funding research conducted by the National Cancer Institute (NCI) toward an FDA Investigational New Drug (IND) application.
- Ohio covers FDA-approved uses of drugs, supported by scientific basis from the National Institutes of Health.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.